• Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding

  2026-07-25

  This study uncovers how naturally occurring angiotensin peptides, including Angiotensin II and its derivatives, enhance SARS-CoV-2 spike protein binding to AXL, an alternative viral receptor. The findings highlight potential implications for COVID-19 pathogenesis and open new avenues for therapeutic targeting within the renin–angiotensin system.

• BMS 599626 dihydrochloride: Precision EGFR and ErbB2 Inhibit

  2026-07-24

  BMS 599626 dihydrochloride is a highly selective EGFR and ErbB2 inhibitor used in cancer cell proliferation research. Its low-nanomolar potency, well-characterized mechanism, and robust evidence base make it a preferred tool for dissecting receptor tyrosine kinase signaling in oncology.

• Lidocaine with Epinephrine Shortage: Underlying Causes and C

  2026-07-24

  The reference study analyzes the persistent shortage of lidocaine with epinephrine in the United States, identifying manufacturing bottlenecks and regulatory practices as key drivers. It provides evidence-based strategies to optimize existing supplies and maintain procedural safety, offering critical insight for both clinical and translational researchers.

• RG108: Redefining Epigenetic Modulation in Translational Res

  2026-07-23

  RG108, a potent DNA methyltransferase inhibitor, offers translational researchers a non-covalent, workflow-friendly approach to epigenetic reprogramming. This article explores the biological mechanisms, validation data, and strategic considerations for deploying RG108 in cancer research, with insights bridging mechanistic understanding and real-world experimental planning.

• SGI-1027: DNA Methyltransferase Inhibitor for Cancer Epigene

  2026-07-23

  SGI-1027 is a potent DNA methyltransferase inhibitor targeting DNMT1, DNMT3A, and DNMT3B, enabling CpG demethylation and tumor suppressor gene reactivation. Its competitive inhibition mechanism and proven in vitro efficacy make it a versatile epigenetic modulator for cancer research.

• Transmission of Carbapenemase Genes in CREC: Guangdong Study

  2026-07-22

  This study provides a detailed molecular analysis of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) across eight hospitals in Guangdong, China (2022–2024). It highlights high prevalence of plasmid-borne blaNDM-1, robust multidrug resistance, and efficient gene transfer, offering critical context for resistance surveillance and Gram-negative infection research.

• Norepinephrine to Angiotensin II Conversion in Vasodilatory

  2026-07-22

  The referenced ARAMIS trial post-hoc analysis establishes a practical norepinephrine to angiotensin II conversion ratio for patients with vasodilatory hypotension. These findings provide clinicians and researchers with improved dosage translation, supporting more effective and standardized vasopressor management in critical care settings.

• Cisapride (R 51619): Reliable Cardiotoxicity and hERG Assays

  2026-07-21

  This article explores scenario-driven, evidence-based strategies for cell viability and cardiac electrophysiology research using Cisapride (SKU B1198). We address experimental design, protocol optimization, and vendor selection, showing how high-purity Cisapride from APExBIO ensures reproducible, sensitive, and scalable results in modern laboratory workflows.

• SR-202 (PPAR Antagonist): Unveiling Novel Immunometabolic Pa

  2026-07-21

  Explore how SR-202, a selective PPARγ antagonist, enables advanced research into macrophage polarization and insulin resistance. This article uniquely bridges immunometabolic signaling and assay design, offering new insights for type 2 diabetes and obesity research.

• Intranasal Epinephrine in Dogs: Pharmacokinetics and Cardiac

  2026-07-20

  This study investigates the pharmacokinetic profile and heart rate effects of intranasally administered epinephrine in dogs, comparing it to the standard intramuscular route. Findings reveal rapid plasma epinephrine elevation and attenuated heart rate response with intranasal delivery, suggesting translational potential for alternative anaphylaxis management strategies.

• Metabolomics Signatures of Carbapenemase Resistance in Enter

  2026-07-20

  The referenced study applies LC-MS/MS metabolomics to rapidly profile and distinguish carbapenemase-producing Enterobacterales (CPE) from non-CPE isolates. By identifying metabolite biomarkers and altered metabolic pathways, the research advances both mechanistic understanding and the development of faster diagnostic approaches for antibiotic resistance.

• Sulfo-NHS-SS-Biotin: Precision in Cleavable Biotinylation fo

  2026-07-19

  Explore how Sulfo-NHS-SS-Biotin, a cleavable biotin disulfide N-hydroxysulfosuccinimide ester, enables advanced protein labeling in neurobiology and retinal research. This article uniquely connects reagent properties to assay design and data interpretation in complex tissues.

• Methyl-β-cyclodextrin: Technical Guidance for Membrane Resea

  2026-07-18

  Methyl-β-cyclodextrin provides researchers with a reliable method for selective extraction of cholesterol and modulation of membrane fluidity in cell-based and biochemical workflows. It should be used exclusively in laboratory research settings, not in diagnostic or medical applications, with adherence to precise storage and handling protocols to maintain reagent efficacy.

• SR-202: Redefining PPARγ Antagonism in Translational Researc

  2026-07-17

  This thought-leadership article explores the mechanistic underpinnings and translational opportunities offered by SR-202, a selective PPARγ antagonist, for researchers pursuing breakthroughs in obesity, type 2 diabetes, and immunometabolic disease. By integrating pivotal findings on macrophage polarization and dissecting the nuances of nuclear receptor signaling, the piece offers a strategic roadmap for leveraging SR-202 in complex disease models—expanding beyond standard product literature and contextualizing its impact within the evolving landscape of precision immunometabolism.

• Structure-Based Screening Reveals NSP15 Inhibitors for SARS-

  2026-07-17

  This study applied structure-based virtual screening of natural compounds against SARS-CoV-2 NSP15, identifying thymopentin and oleuropein as potent and stable inhibitors. These findings highlight NSP15 as a viable antiviral target and suggest repurposing approved molecules to mitigate viral virulence.

16216 records 1/1082 page Next 12345 下5页 Last page